73478
document
Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma : a randomized phase II study . In a phase II study 119 patients with disseminated malignant melanoma were randomized to receive treatment with dacarbazine alone or in combination with vindesine . The study was designed to reveal an additive response rate when the drugs were combined . Dacarbazine was given i.v . at 250 mg m-2 per day X V every 4 weeks . In the combination regimen vindesine given at 3 mg m-2 per week was included . One hundred and ten patients were available for evaluation of response . With dacarbazine 4/51 patients obtained a complete remission ( 8 % ) and 5/51 patients a partial remission ( 10 % ) . Overall response rate was 18 % . With dacarbazine-vindesine 8/59 patients obtained a complete remission ( 13 % ) and 7/59 patients a partial remission ( 12 % ) . Overall response rate was 25 % . The difference in response rates observed between the treatment arms is not statistically significant . Median response duration was 123 days for dacarbazine patients and 171 days for patients receiving dacarbazine-vindesine ( difference not statistically significant ) .
73479
Intervention_Pharmacological
Dacarbazine
73480
Intervention_Pharmacological
dacarbazine-vindesine
73481
Intervention_Pharmacological
dacarbazine
73482
Intervention_Pharmacological
Dacarbazine was given i.v
73483
Intervention_Pharmacological
vindesine
73484
Intervention_Pharmacological
dacarbazine
73485
Intervention_Pharmacological
dacarbazine-vindesine
73486
Outcome_Other
complete remission
73487
Outcome_Other
partial remission
73488
Outcome_Other
Overall response rate
73489
Outcome_Other
complete remission
73490
Outcome_Other
partial remission
73491
Outcome_Other
Overall response rate
73492
Outcome_Physical
response rates
73493
Participant_Sample-size
119 patients
73494
Participant_Condition
disseminated malignant melanoma
73495
Participant_Sample-size
One hundred and ten